ArticleRadiology2023
Axillary Lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 Vaccination: MRI Evaluation.
Article in Radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Not Everything That Shines Is Gold: Reactive Lymphadenopathy After COVID-19 Vaccination in a Breast Cancer Survivor.Journal of general internal medicine · 2025Article
- Axillary Lymphadenopathy after COVID-19 Vaccination: Follow-up for Enlarged Lymph Nodes on MR Imaging.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Article
- COVID-19 vaccine-associated lymphadenopathy: a review.Le infezioni in medicina · 2024Review
- Article
- Axillary lymph nodes enlargement after Sars-CoV-2 vaccine in patients undergoing breast examination: a single-centre experience in 285 women.La Radiologia medica · 2023Article
- Article
- Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis.Epidemiology and health · 2023Article
- Coronary Artery Disease and Axillary Lymphadenopathy Post COVID-19 Vaccine Administration: Insights from Tl-201 Myocardial Perfusion Imaging.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background COVID-19 vaccination-related axillary lymphadenopathy has become an important problem in cancer imaging. Data are needed to update or support imaging guidelines for conducting appropriate follow-up. Purpose To investigate the prevalence, predisposing factors, and MRI characteristics of COVID-19 vaccination-related axillary lymphadenopathy. Materials and Methods Prospectively collected prevaccination and postvaccination chest MRI scans were secondarily analyzed. Participants who underwent two doses of either the Pfizer-BioNTech or Moderna COVID-19 vaccine and chest MRI from June to October 2021 were included. Enlarged axillary lymph nodes were identified on postvaccination MRI scans compared with prevaccination scans. The lymph node diameter, signal intensity with T2-weighted imaging, and apparent diffusion coefficient (ADC) of the largest enlarged lymph nodes were measured. These values were compared between prevaccination and postvaccination MRI by using the Wilcoxon signed-rank test. Results Overall, 433 participants (mean age, 65 years ± 11 [SD]; 300 men and 133 women) were included. The prevalence of axillary lymphadenopathy in participants 1-14 days after vaccination was 65% (30 of 46). Participants with lymphadenopathy were younger than those without lymphadenopathy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.